Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Tafamidis (ATC-Code: N07XX08) in der Wirkstärke 20mg innerhalb des Zeitraumes vom 01.12.2026 bis zum 30.11.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient Tafamidis (ATC code: N07XX08) at the strength of 20 mg, AOK Niedersachsen offers it. The health insurance fund, for the period until the entry into force of exclusive agreements as a result of a formal procurement procedure in accordance with the provisions of Part 4 of the GWB, offers rebate agreements to all interested pharmaceutical companies, without a selection decision. The contract award(s) take place within the framework of an “open-house model” and serve as a bridge between the start of generic competition (expiry of the patent) and the award of exclusive rebate agreements. The contracts offered are not exclusive; contracts with all market participants (pharmaceutical companies) are desired by AOK Niedersachsen. Under the open-house model, uniform conditions apply to all participants. Contract content, terms and conditions and access procedures are uniform—individual negotiations are generally not conducted. The contract terms are for a maximum of twenty-four months; the earliest contract start date is 01.12.2026. All contracts end no later than 30.11.2028, irrespective of the date on which the respective contract is concluded. Entry into the…

TENDER BRIEF

TENDER DOCUMENTS